BCS1L

Across TCGA pan-cancer cohorts, BCS1L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BCS1L data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher BCS1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BCS1L expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, UCEC, and PRAD are the cancer types where BCS1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.138	0.776	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	All	1.000	0.331	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BCS1L–LUSC (OS)

Open the LUSC breakdown →